Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Inclusion Criteria:

1. Participant has a histologically or pathologically confirmed diagnosis of StageIIIC, IIID, or IV unresectable or metastatic melanoma.

2. In the investigator's assessment, the participant has an Eastern CooperativeOncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancyof > 6 months.

3. Participant is assessed as having at least one resectable lesion (or aggregatelesions) for lifileucel generation.

4. Participant must have at least one measurable disease as defined by RECIST 1.1following tumor resection.

5. Participants must have adequate organ function.

6. Participants of childbearing potential or those with partners of childbearingpotential must be willing to practice an approved method of highly effective birthcontrol.

7. Participants who are > 70 years of age may be allowed to enroll after theinvestigator discusses with the medical monitor.

Exclusion Criteria:

1. Participant has melanoma of uveal/ocular origin.

2. Participant has symptomatic untreated brain metastases.

3. Participant received more than 1 prior line of therapy.

4. Participant received prior therapy for metastatic disease

5. Participants with a BRAF V600 mutation-positive tumor received prioradjuvant/neoadjuvant ICI therapy only

6. Participant has an active medical illness(es) that, in the opinion of theinvestigator, would pose increased risks for study participation, such as systemicinfections; seizure disorders; coagulation disorders; or other active major medicalillnesses of the cardiovascular, respiratory, or immune systems.

7. Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).

8. Participant had another primary malignancy within the previous 3 years (except forthose that do not require treatment or were curatively treated >1 year ago, and inthe judgment of the investigator do not pose a significant risk of recurrence.)

9. Participant has a history of allogeneic cell or organ transplant.

Other protocol defined inclusion/exclusion criteria could apply.